Trials / Terminated
TerminatedNCT01799889
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 326 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to evaluate efficacy of entospletinib in participants with relapsed or refractory hematologic malignancies. Participants with the following relapsed or refractory hematologic malignancies will be enrolled into the study: relapsed or refractory chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), or non-FL indolent non-Hodgkin lymphomas (iNHL; including lymphoplasmacytoid lymphoma/ Waldenström macroglobulinemia \[LPL/WM\], small lymphocytic lymphoma \[SLL\], or marginal zone lymphoma \[MZL\]).
Conditions
- Chronic Lymphocytic Leukemia
- Mantle Cell Lymphoma
- Diffuse Large B-cell Lymphoma
- Non-FL Indolent Non-Hodgkin's Lymphoma
- Follicular Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Entospletinib MM | Entospletinib MM tablet administered orally |
| DRUG | Entospletinib SDD | Entospletinib SDD tablet administered orally |
Timeline
- Start date
- 2013-03-14
- Primary completion
- 2017-09-14
- Completion
- 2020-01-30
- First posted
- 2013-02-27
- Last updated
- 2020-11-19
- Results posted
- 2020-09-23
Locations
48 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01799889. Inclusion in this directory is not an endorsement.